News › Industry News, News

Revance Commercial Infrastructure Established and Positioned to Launch Prestige Aesthetics Portfolio

August 31, 2020

Revance Therapeutics, Inc., a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its investigational neuromodulator product, DaxibotulinumtoxinA for Injection, has announced that the company’s field force is established and will begin introducing its prestige aesthetics portfolio, including the RHA Collection of dermal fillers, resilient hyaluronic acid and the HintMD financial technology platform, in the United States in September.
Read more at Business Wire >>

Become a member

Get the tools you need to succeed in the medical spa industry.

Related
    • AmSpa CEO Reflects on the Sonya Dakar Case
    • SkinStylus Receives New FDA Clearance for the Improvement of Periorbital Wrinkles for All Skin Types
    • GlossGenius Becomes Platinum Vendor Affiliate with the American Med Spa Association
    • FDA Advisory Committee to Review Seven Peptides for Potential Use in Compounding
    • Medicare GLP-1 Bridge Program Launches July 1, Expanding Access for Some Patients
Advertisement